Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that prostatitis, affecting many men aged 30 to 50, arises from diverse causes, including bacterial infections and pelvic pain syndromes, and requires treatment strategies specific to its type, such as antibiotics and lifestyle changes.

This review focuses on recent advancements in understanding and treating ischemic and nonischemic priapism, but does not present new clinical results.

This study reported that 44% of hirsute women undergoing cyproterone acetate treatment experienced impaired sexual enjoyment, highlighting the need to inform patients about potential side effects.

This review reports that androgenetic alopecia in young adult men is consistently linked to lower self-esteem, increased anxiety, and a higher risk of depression, suggesting significant psychosocial impacts beyond cosmetic concerns.

This review discusses the negative effects of anabolic androgenic steroids on various organ systems in men and reports no new results, highlighting the need for physician awareness.

This study in Senegal reported that among women with hyperandrogenism, the primary diagnosis was polycystic ovarian syndrome, with symptoms including hirsutism, menstrual disorders, and acne.

This article discusses the systematic diagnostic evaluation of secondary amenorrhea and provides guidance for referral considerations; it reports no new research findings.

This case study describes a 45-year-old man who developed post-finasteride syndrome with various symptoms after stopping Finasteride, highlighting the condition's rarity and poorly understood pathophysiology.

This article reviews various side effects and concerns related to oral contraceptives, including potential vascular complications and elevated plasma cortisol levels, but reports no new clinical results.

This case report describes an atypical postfinasteride syndrome in a patient treated with both dutasteride and finasteride for androgenic alopecia, highlighting its multisystem involvement and irreversible nature.

This review discusses the adverse effects of finasteride for male androgenic alopecia, highlighting depressive symptoms and persistent sexual dysfunction, and reports no new clinical findings.

This study outlines a multidisciplinary approach to investigate primary amenorrhea, emphasizing the necessity to consider medical history, physical examination, and potential hormonal or anatomical causes, and recommends early referral in cases of chromosomal abnormalities or persistent amenorrhea following the development of secondary sexual characteristics.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.

This review examines the roles of androgens in women's health and provides recommendations for androgen therapy but reports no new results.

This paper discusses the potential relationship between finasteride's adverse effects and factors like hand preference and sexual orientation, suggesting these could influence risk in male androgenic alopecia treatment, but reports no new clinical results.

This chapter reviews selective androgen receptor modulators, discussing their therapeutic potential beyond current androgen applications, and reports no new clinical findings.

This study found that finasteride significantly reduced dihydrotestosterone levels but did not provide clear evidence of impaired libido or erectile function compared to placebo in men.

In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.

This study found that finasteride treatment in males with androgenetic alopecia was linked to significant changes in sperm parameters and increased testosterone levels, but no sexual dysfunction was observed, and sperm parameters returned to baseline after treatment stopped.

This study evaluated potential penile vascular changes and persistent adverse effects in men discontinuing 5α-reductase inhibitors for androgenic alopecia, but no new clinical results were reported.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

Finasteride slightly improves prostate symptoms but has minimal difference from placebo.

This study found that red ginseng oil (RXGIN) significantly improved lower urinary tract symptoms and some aspects of sexual function in men, with no serious adverse events reported.

This review discusses the occurrence of persistent sexual, physical, neurological, and psychiatric side effects known as post-finasteride syndrome after 5x-reductase inhibitor treatment, and emphasizes the importance of evaluating these risks for patients with benign prostatic hyperplasia or androgenic alopecia.

This study found that after 12 weeks of taking the trial product SHPro®, participants reported improvements in prostate symptom scores and erectile function, with confirmed safety.

This research overview discusses Post-Finasteride Syndrome, presenting data from an FDA database, but it does not report any new clinical findings.

This study systematically reviewed dermatological conditions affecting transgender and gender-diverse individuals, highlighting that testosterone therapy can induce acne in 25–88% of transgender men and alopecia after over two years, while dermatologic care must consider both medical and social complexities.